| Revision as of 13:58, 21 November 2011 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 447739967 of page Haloprogin for the Chem/Drugbox validation project (updated: 'DrugBank'). |
Latest revision as of 13:45, 30 January 2023 edit Entranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,412 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper |
| Line 1: |
Line 1: |
|
|
{{Short description|Chemical compound}} |
|
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}} |
|
|
|
{{Redirect|Polik}} |
|
{{Drugbox |
|
{{Drugbox |
|
| verifiedrevid = 411546100 |
|
| verifiedrevid = 461766483 |
|
| IUPAC_name = 1,2,4-trichloro-5-benzene |
|
| IUPAC_name = 1,2,4-Trichloro-5-benzene |
|
| image = Haloprogin.png |
|
| image = Haloprogin.svg |
|
| image2 = |
|
| image2 = |
|
|
|
|
|
<!--Clinical data--> |
|
<!--Clinical data--> |
|
| tradename = |
|
| tradename = |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_US = <!-- A / B / C / D / X --> |
|
| pregnancy_category = |
|
| pregnancy_category = |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> |
|
|
| legal_US_comment = Not available |
|
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> |
|
|
| legal_status = Not available in U.S. |
|
| legal_status = |
|
| routes_of_administration = Topical |
|
| routes_of_administration = ] |
|
|
|
|
|
<!--Pharmacokinetic data--> |
|
<!--Pharmacokinetic data--> |
|
| bioavailability = |
|
| bioavailability = |
|
| protein_bound = |
|
| protein_bound = |
|
| metabolism = |
|
| metabolism = |
|
| elimination_half-life = |
|
| elimination_half-life = |
|
| excretion = |
|
| excretion = |
|
|
|
|
|
<!--Identifiers--> |
|
<!--Identifiers--> |
|
| CASNo_Ref = {{cascite|correct|CAS}} |
|
| CAS_number_Ref = {{cascite|correct|??}} |
|
| CAS_number = 777-11-7 |
|
| CAS_number = 777-11-7 |
|
| ATC_prefix = D01 |
|
| ATC_prefix = D01 |
| Line 43: |
Line 44: |
|
|
|
|
|
<!--Chemical data--> |
|
<!--Chemical data--> |
|
| C=9 | H=4 | Cl=3 | I=1 | O=1 |
|
| C=9 | H=4 | Cl=3 | I=1 | O=1 |
|
| molecular_weight = 361.39 g/mol |
|
|
| smiles = Clc1cc(OCC#CI)c(Cl)cc1Cl |
|
| smiles = Clc1cc(OCC#CI)c(Cl)cc1Cl |
|
| InChI = 1/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 |
|
|
| InChIKey = CTETYYAZBPJBHE-UHFFFAOYAB |
|
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} |
|
| StdInChI = 1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 |
|
| StdInChI = 1S/C9H4Cl3IO/c10-6-4-8(12)9(5-7(6)11)14-3-1-2-13/h4-5H,3H2 |
| Line 53: |
Line 51: |
|
| StdInChIKey = CTETYYAZBPJBHE-UHFFFAOYSA-N |
|
| StdInChIKey = CTETYYAZBPJBHE-UHFFFAOYSA-N |
|
| melting_point = 113.5 |
|
| melting_point = 113.5 |
|
| solubility = insoluble |
|
| solubility = Insoluble |
|
}} |
|
}} |
|
|
|
|
|
'''Haloprogin''' is an ] drug used to treat ] and other ] ]s.<ref name="pmid161212">{{cite journal | vauthors = Rudolph RI | title = Haloprogin as treatment for fungal infections | journal = Clinical and Experimental Dermatology | volume = 4 | issue = 4 | pages = 548 | date = December 1979 | pmid = 161212 | doi = 10.1111/j.1365-2230.1979.tb01656.x | s2cid = 71471801 }}</ref> It is marketed in creams under the trade names '''Halotex''', '''Mycanden''', '''Mycilan''', and '''Polik'''. |
|
|
|
|
|
==Action== |
|
|
Haloprogin was previously used in 1% topical creams as an antifungal agent. It was marketed ] primarily to treat ] infections of the ]. The mechanism of action is unknown.<ref>{{cite web |
|
|
| title =Haloprogin |
|
|
| work =Drugs@FDA |
|
|
| publisher =] |
|
|
| url = http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName=HALOTEX |
|
|
| access-date = 2007-02-17 }}</ref> |
|
|
|
|
|
Haloprogin had a high incidence of side effects including: irritation, burning, vesiculation (blisters), scaling, and itching. It has since been discontinued due to the emergence of more modern antifungals with fewer side effects.<ref>{{cite web |
|
|
| title = Haloprogin |
|
|
| work = DrugBank |
|
|
| publisher = University of Alberta |
|
|
| date =Nov 6, 2006 |
|
|
| url =http://redpoll.pharmacy.ualberta.ca/drugbank/cgi-bin/getCard.cgi?CARD=APRD01011.txt |
|
|
| access-date = 2007-02-17 }}</ref> |
|
|
|
|
|
==References== |
|
|
<references /> |
|
|
|
|
|
{{Antifungals}} |
|
|
{{Xenobiotic-sensing receptor modulators}} |
|
|
|
|
|
] |
|
|
] |
|
|
] |
|
|
] |
|
|
|
|
|
{{antiinfective-drug-stub}} |
|
|
{{dermatologic-drug-stub}} |